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Nonhealing diabetic wounds are associated with
impaired macrophage (Mf) function. Leukocytes
and platelets (PLT) play crucial roles in wound
healing by poorly understood mechanisms. Here
we report the identification and characterization
of the maresin-like(L) mediators 14,22-dihydroxy-
docosa-4Z,7Z,10Z,12E,16Z,19Z-hexaenoic acids,
14S,22-diHDHA (maresin-L1), and 14R,22-diHDHA
(maresin-L2) that are produced by leukocytes
and PLT and involved in wound healing. We show
that 12-lipoxygenase-initiated 14S-hydroxylation or
cytochrome P450 catalyzed 14R-hydroxylation and
P450-initiated u(22)-hydroxylation are required
for maresin-L biosynthesis. Maresin-L treatment
restores reparative functions of diabetic Mfs, sug-
gesting that maresin-Ls act as autocrine/paracrine
factors responsible for, at least in part, the reparative
functions of leukocytes andPLT inwounds. Addition-
ally, maresin-L ameliorates Mf inflammatory activa-
tion and has the potential to suppress the chronic
inflammation in diabetic wounds caused by activa-
tion of Mfs. These findings provide initial insights
intomaresin-L biosynthesis andmechanismof action
and potentially offer a therapeutic option for better
treatment of diabetic wounds.
INTRODUCTION
Successful wound healing entails complex cellular and molecu-
lar processes involving diverse interactions of growth factors,
cytokines, lipid mediators, resident cells, leukocytes, platelets
(PLTs), and stem cells (Brem and Tomic-Canic, 2007). Soon after
wounding, PLTs aggregate at the injury site to stop bleeding.
Neutrophils are recruited, followed by monocytes (MCs) and
other leukocytes, which prevent wound infection and/or phago-
cytose cell debris and infecting microbes. After infiltrating the
wounds, leukocytes and PLTs can produce growth factors, cyto-
kines, and lipid mediators that regulate fibroblasts, epithelial1318 Chemistry & Biology 21, 1318–1329, October 23, 2014 ª2014 Ecells, and other resident cells as well as recruit stem cells for
the repair (Hong et al., 2003; Lu et al., 2010; Phinney and
Prockop, 2007). Macrophages (Mfs) in wounds are mainly differ-
entiated from recruited blood MCs and play indispensable roles
in wound healing during postnatal life. Mfs accelerate re-epithe-
lialization by activating epithelial cells and increase granulation
tissue formation by recruiting fibroblasts and endothelial cells
into wounded skin (Eming et al., 2007; Koh and DiPietro, 2011).
Diabetes results in delayed healing or nonhealing of wounds.
Diabetic wounds that do not heal can result in suffering, poor
quality of life, and high mortality (Brem and Tomic-Canic, 2007).
Diabetes impairs themolecular and cellular processes of healing,
including the reparative functionsofMfs (Khannaet al., 2010; Tian
et al., 2011b). Diabetic Mfs are deficient in the production of pro-
healing growth factors and the promotion ofwound re-epitheliza-
tion and vascularization. Restoration of the reparative functions
ofMfs represents a potentially effective strategy for the treatment
of diabetic wounds and is a major focus of this study.
PLTs, Mfs, MCs, and polymorphonuclear neutrophils (PMNs)
transform docosahexaenoic acid (DHA) into proresolution lipid
mediators, which include resolvins (Serhan et al., 2002) and neu-
roprotectin D1/protectin D1(Hong et al., 2003; Marcheselli et al.,
2003), along with 14-hydroxy-carrying maresins (Serhan et al.,
2009) aswell as 14-hydroxy- andu-1-hydroxy-carrying 14,21-di-
hydroxy-DHAs (14,21-diHDHAs) (Lu et al., 2010). P450 u-hy-
droxylasesdeactivate LTB4 to 20-hydroxyl LTB4P450 (Capdevila
et al., 2005) andconvert resolvin E1 to20-hydroxy resolvin E1 that
retains bioactivity (Hong et al., 2008). Studies show thatmaresin1
(Serhan et al., 2009), neuroprotectin D1/protectin D1, resolvin D1
(Gronert et al., 2005; Hellmann et al., 2012; Tang et al., 2013), and
14,21-diHDHAs (Hocking, 2012; Lu et al., 2010; Tian et al., 2011a,
2011b) promote wound healing. Moreover, 14S,21R-diHDHA
recovers the reparative functions of diabetic Mfs (Tian et al.,
2011b). Therefore, lipid mediators may be responsible, in part,
for the roles of leukocytes and PLTs in wound healing.
This background information led us to form two hypotheses ad-
dressed in this report. (1) Leukocytes andPLTs, by 12-lipoxygena-
se(LO)-hydroxylase and P4506-hydroxylase catalysis in tandem,
convertDHAtodocosanoids thatcarryboth14-hydroxyand6-hy-
droxy. (2) These compounds act in an autocrine/paracrinemanner
that restores diabetes-impaired Mf functions in promoting the
migration of epithelial cells and fibroblasts, the cellular processes
known to be critical to wound healing, and in recruiting MSCs.lsevier Ltd All rights reserved
Figure 1. Structure Identification and Elucidation of 14,22-Dihydroxy-4,7,10,12,16,19-Docosahexaenoic Acids Produced from DHA by
Human Leukocytes with or without Platelets
Human blood leukocytes (3 3 106 monocytes + 3 3 107 neutrophils + 3 3 106 lymphocytes) were incubated with or without 3 3 107 platelets in 3 mM DHA or
DHA-21,21,22,22,22-d5 and then stimulated by wound healing-relevant conditions. Leukocytes were also incubated with 3 mM 14S-HDHA or 14R-HDHA and
then stimulated. The incubations were analyzed by aR chiral LC-UV-MS (AD-RH column).MS/MS andUV (inset) spectra of aR chiral LC-MS/MS chromatographic
peaks demonstrate the structures (right). Diagnostic MS/MS ions are interpreted in the insets. Representative results are shown (n = 3).
(A) MS/MS UV spectra of 14,22-diHDHA for peak II in (C).
(B) MS/MS UV spectra of DHA-d5-derived 14,22-diHDHA-d4 corresponding to peak II in (C).
(C) Chromatograms of aR chiral LC-MS/MS for 14R,22-diHDHA and 14S,22-diHDHA generated from 14R-HDHA (top) and 14S-HDHA (center), respectively, by
leukocytes or for both 14,22-diHDHAs generated from DHA (bottom) by leukocytes with or without platelets.
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epithelialization by epithelial cells is essential to covering wounds.
Also, collagendepositionby fibroblasts is critical towound healing
that has high breaking strength and no dehiscence (Li et al., 2013;
Ranzer et al., 2011; Yeh et al., 2009). To test these hypotheses, we
studied MCs, PMNs, and lymphocytes (LYMs) isolated from
human blood, Mfs from L12-LO-deficient (L12-LO/ or 12/15-
LO/) mice and wild-type controls, and type II diabetic db/db
mice and nondiabetic db/+ controls. We used aqueous reverse-
phasechiral liquidchromatographywithdiodearrayUVspectrom-
etry and tandem mass spectrometry (aR chiral LC-UV-MS/MS)
and deuterium-labeled compounds for structure elucidation and
identification of compounds. The bioactions of these compounds
ondb/dbMfswerestudied regarding thepromotionofmigrationof
scratch-wounded epithelial cells and fibroblasts and transmigra-
tion of MSCs, regarding generation of hepatocyte growth factor
(HGF), and regarding inflammatory activation.
RESULTS
Structure Elucidation and Identification of 14-Hydroxy
and 6-Hydroxy-Containing Compounds Produced from
n3-Docosahexaenoic Acid by Human Blood Leukocytes
and Platelets
Leukocytes and PLTs play crucial reparative roles in wound
healing and produce prohealing resolvins, maresins (Serhan
et al., 2009), and/or 14,21-diHDHAs (Hellmann et al., 2012;Chemistry & Biology 21, 1318–1Lu et al., 2010; Tian et al., 2011b). To test a part of our first
hypothesis, we incubated human blood leukocytes (MCs +
PMNs + LYMs) with or without PLTs in 3 mM DHA (a level found
in wounds) (Tian et al., 2011a) and then activated the cells with
factors involved in wound healing. The incubations were studied
via aR chiral LC-UV-MS/MS. 14,22-dihydroxy 4,7,10,12,16,19-
docosahexaenoic acids (14,22-diHDHAs) and their deuterium-
labeled isotopomers were generated by these cells from
DHA and deuterium-labeled DHA-21,21,22,22,22-d5 (DHA-d5),
respectively (Figure 1). The molecular structure elucidation and
identification were conducted as follows.
In the MS/MS spectra at a mass-to-charge ratio (m/z) 359
[M-H] of 14,22-diHDHAs, represented by the spectrum in Fig-
ure 1A for chromatographic peak II in Figure 1C, the fragment
ions m/z 341 [M-H-H2O]
, 323 [M-H-2H2O]
, 297 [M-H-H2O-
CO2]
, and 279 [M-H-2H2O-CO2]
 were consistent with one car-
boxy andamolecularweight (M) of 360daltons (Da). The fragment
ionsm/z205, 161 [205-CO2]
, 233, and189 [233-CO2]
 showeda
hydroxy at the 14 position (C14). Ion m/z 329, generated from
cleavage of the C21-C22 bond, in conjunction with ions m/z
311 [329-H2O]
, 285 [329-CO2]
, and 267 [329-H2O-CO2]
,
demonstrated another hydroxy at C22. The identification of
14,22-diHDHA was confirmed by LC-MS/MS spectral ions of
14,22-diHDHAs-d4 (Figure 1B), which was generated from DHA-
d5 and is illustrated in the insets for MS/MS fragmentation inter-
pretation (Figures 1A and 1B, right insets). Fragment ions from
MS/MS at m/z 363 [M-H] of 14,22-diHDHAs-d4 are m/z 345329, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1319
Figure 2. The Intermediates 22-HDHA, 14R-HDHA, and 14S-HDHA
Were Generated from DHA by Human Blood Leukocytes plus Plate-
lets or Platelets
Human blood platelets (3 3 107) or leukocytes + platelets (3 3 106
monocytes + 3 3 106 neutrophils + 3 3 106 lymphocytes + 3 3 107 platelets)
were incubated with 3 mMDHA or DHA-21,21,22,22,22-d5 and then stimulated
as in Figure 1. The incubations were analyzed by aR chiral LC-UV-MS (IA
column) (n = 3).
(A) 22-HDHA was identified from leukocytes + platelets by its MS/MS spec-
trum of the aR chiral LC-MS/MS chromatographic peak in (B).
(B) 22-HDHA produced by leukocytes + platelets, shown by its aR chiral
LC-MS/MS chromatogram.
(C) MS/MS spectrum of 22-HDHA-d4 generated from DHA-21,21,22,22,22-d5.
(D) 14S-HDHA and 14R-HDHA produced by platelets shown by an aR chiral
LC-MS/MS chromatogram.
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, 327 [M-H-2H2O]
, 301 [M-H-H2O-CO2]
, 283 [M-H-
2H2O-CO2]
, 331, 313 [331-H2O]
, 287 [331-CO2]
, 269 [331-
H2O-CO2]
, 233, 189 [233-CO2]
, 205, and 161 [205-CO2]
.
One deuterium at C22 was replaced by 22-hydroxy, whereas the
other four deuterium atoms remained at C21 and C22, rendering
the molecular ion of 14,22-diHDHA-d4 as m/z 363 [M-H]
. The
UV spectra of 14,22-diHDHAs were consistent with that of
14,22-diHDHA-d4, for which the maximum absorbance wave-
length (lmax) was235nm (Figures1Aand1B, left insets), therefore
confirming a pair of conjugated double bonds in their structures.
Peak I in the LC-MS/MS chromatogram possessed a shorter
retention time than peak II but had MS/MS and UV spectra
indistinguishable from peak II. Therefore, peak I and peak II
were stereoisomers of 14,22-HDHAs (Figure 1C, bottom). They
were produced by human leukocytes and PLTs from DHA.
Ournextaimwas todetermine thestereochemistryofpeak I and
II 14,22-HDHAs (Figure 1C, bottom). The only asymmetric carbon
in the 14,22-diHDHA stereoisomers is C14, which can lead to two1320 Chemistry & Biology 21, 1318–1329, October 23, 2014 ª2014 Eenantiomers (14R,22-diHDHA and 14S,22-diHDHA) where the
double-bondgeometry of 14S-HDHAor 14R-HDHA is considered
to be biosynthetically conserved, similar to the u oxidation of ei-
cosanoids catalyzed by P450 (Capdevila et al., 2005). A single
14,22-diHDHA aR chiral LC-MS/MS peak (Figure 1C, top) was
detected, at a shorter retention time, from the incubation of
14R-HDHA with leukocytes. This peak possessed MS/MS and
UV spectra indistinguishable from those in Figure 1A for 14,22-
diHDHA. Therefore, this peak was identified as 14R,22-diHDHA.
In parallel, a single 14,22-diHDHA aR chiral-MS/MS peak (Fig-
ure 1C, center) was also found, at a longer retention time, from in-
cubation of 14S-HDHAwith leukocytes. Again, this peak hadMS/
MS and UV spectra indistinguishable from those in Figure 1A for
14,22-diHDHA, thus, this peak was identified as 14S,22-diHDHA.
The shorter retention time for 14R,22-diHDHA derived from 14R-
HDHA (Figure 1C, top), compared with 14S,22-diHDHA derived
from 14S-HDHA (Figure 1C, center), is consistent with the reports
that anR-hydroxy enantiomer has a shorter retention time than its
S-epimer under identical aR chiral LC conditions (Lu et al., 2010).
Therefore, leukocytes with and without PLTs converted DHA to
14R,22-diHDHA and 14S,22-diHDHA.
P450 and 12-LO Are Key Enzymes in the Biosynthetic
Pathways for 14S,22-diHDHA and 14R,22-diHDHA
We then tested thepart of our first hypothesis that leukocytes and
PLTs convert DHA to 14,22-diHDHAs by 12-LO- and P450-u-hy-
droxylase catalysis in tandem or P450 alone. Based on previous
information gained from the biosynthesis of 14S,21R/S-diHDHAs
and 14R,21R/S-diHDHAs (Lu et al., 2010), we made three
predictions. (1) The 22-hydroxy in both 14R,22-diHDHA and
14S,22-diHDHA results from P450 u-hydroxylase, analogous to
the generation of the 22-hydroxy in 22-HDHA (VanRollins et al.,
1984). (2) The 14R-hydroxy in 14R,22-diHDHA is generated
by P450, analogous to the 14R-hydroxy in P450-generated
14R-HDHA (Figure S1 available online). (3) 14S-hydroxy in
14S,22-diHDHA results from 12-LO-catalyzed lipoxygenation,
analogous to the generation of the 14S-hydroxy in 14S-HDHA
(Lu et al., 2010). Our aR chiral LC-UV-MS/MS analysis showed
that human blood leukocytes and PLTs converted DHA to 22-
HDHA (Figures 2A and 2B) and to 14S-HDHA and 14R-HDHA
(Figure 2D) in addition to 14S,22-diHDHA and 14R,22-diHDHA
(Figure 1), which is consistent with the three predictions.
22-HDHA was identified based on MS/MS ions m/z 269, 281,
299, 313, and 325 (Figure 2A) of the chiral LC peak detected from
the incubation of leukocytes, PLTs, and DHA (Figure 2B). This
observed 22-HDHA was confirmed by the 22-HDHA-d4 bio-
synthesized from DHA-d5, where 22-HDHA-d4 possessed an
LC chromatogram and MS/MS spectrum with ions m/z 271,
285, 303, 315, and 329 (Figure 2C), consistent with those of
22-HDHA. The UV spectrum of 22-HDHA or 22-HDHA-d4 had
a single band with lmax 205 nm, consistent with the six no-con-
jugate double bonds in each compound (Figures 2A and 2C,
insets). 22-HDHA is a marker for P450 u-hydroxylation of DHA
or DHA derivatives in leukocytes and PLTs because rat liver
microsomal P450 was found to produce 22-HDHA (VanRollins
et al., 1984), and auto-oxidation or oxidation catalyzed by LOs
and cyclooxygenases has been found to not oxidize u-terminal
SP3 carbon (Capdevila et al., 2005; Hong et al., 2003; Lu et al.,
2010).lsevier Ltd All rights reserved
Figure 3. Identification of Pathways in
the Biosynthesis of 14S,22-diHDHA and
14R,22-diHDHA
Inhibition of cytochrome P450 in leukocytes
and platelets diminished production of 14S,22-
diHDHA14R,22-diHDHA, and 22-HDHA; knockout
of L12-LO diminished 14S,22-diHDHA production
by macrophages.
Human blood cells (3 3 106 monocytes + 3 3 106
neutrophils + 3 3 106 lymphocytes + 3 3 108
platelets) were incubated in 3 mM DHA and then
stimulated as in Figure 1, except that the P450
inhibitor 17-ODYA or vehicle alone was added,
10min before DHAwas supplied, and added again
at the same amount when stimulating. Mfs (3 3
106) isolated from L12-LO/ or wild-type control
mice were incubated in 3 mMDHA and stimulated.
Incubations were analyzed via aR chiral LC-UV-
MS with an IA column. Representative results are
shown (n = 3).
(A) Inhibition of P450 diminished the formation of
14S,22-diHDHA, 14R,22-diHDHA, and the inter-
mediate or biosynthetic markers 14R-HDHA and
22-HDHA but not 14S-HDHA.
(B) Knockout of L12-LO diminished Mf formation
of 14S,22-diHDHA and its biosynthetic interme-
diate and marker 14S-HDHA.
See also Figures S1 and S2 and Table S1.
Chemistry & Biology
Maresin-like Mediators of Wound HealingTo further test our predictions, we treated the leukocytes and
PLTs with the P450 inhibitor 17-octadecynoic acid (17-ODYA).
This experiment confirmed the first prediction that P450
determines u (or 22)-hydroxylation forming 14S,22-diHDHA,
14R,22-diHDHA, and 22-HDHA because P450 inhibition
diminished their formation but not the formation of 14S-HDHA
(Figure 3A). P450 inhibition also diminished the formation of
14R-HDHA, confirming our second prediction that P450 deter-
mines 14R-hydroxylation for the formation of 14R-HDHA and
14R,22-diHDHA. These results also suggest that auto-oxidation
is negligible to produce 14R-HDHA or 14R,22-diHDHA under
these conditions.
The quantity of 14R-HDHA or 14R,22-diHDHA generated by
P450 and auto-oxidation (Figures 3A and 4) should be compa-
rable with the amount of 14S-HDHA or 14S,22-diHDHA gener-
ated by P450 and auto-oxidation, respectively, because P450
or auto-oxidation is known to generate S- and R-enantiomers
in a racemic 1:1 ratio (Kim et al., 1990). The results showed
that much less 14R-HDHA and 14R,22-diHDHA than 14S-
HDHA and 14S,22-diHDHA were produced by PLTs (Figures
2D and 4) and leukocytes plus PLTs (Figure 3A), respectively.
Therefore, the 14S-HDHA or 14S,22-diHDHA generated by
P450 and auto-oxidation should be much less than the 14S-
HDHA or 14S,22-diHDHA generated by 12-LO, respectively.
As such, P450 and auto-oxidation have a minor role in DHA
14S-hydroxylation for the biosynthesis of 14S,22-diHDHA.
Leukocytes and PLT converted 14S-HDHA to 14S,22-HDHA
(Figure 1C, center). Therefore, our data support the third pre-
diction for the dominant role of 12-LO in forming 14S-hydroxy
of 14S,22-diHDHA.Chemistry & Biology 21, 1318–1To further test this, we incubated DHA with peritoneal Mfs iso-
lated from L12-LO/ and wild-type control mice and analyzed
extracts with aR chiral LC-UV-MS/MS. The L12-LO/Mfs were
deficient in the production of 14S,22-diHDHAand its biosynthetic
intermediate or pathway marker 14S-HDHA, whereas wild-type
Mfs produced 14S,22-diHDHA and 14S-HDHA (Figure 3B).
Because auto-oxidation, P450, cyclooxygenases, and 5-LO are
not abolished by the L12-LO/, the diminished formation of
14S,22-diHDHA and 14S-HDHA in Mfs by L12-LO/ suggests
that auto-oxidation, P450, cyclooxygenases, and 5-LO are insig-
nificant or ineffective in DHA 14S-hydroxylation for biosynthesis
of 14S,22-diHDHA and 14S-HDHA. Together, these data sub-
stantially confirm our third prediction that 12-LO is a key enzyme
required for 14S-hydroxylation in the biosynthesis of 14S,22-
diHDHA. Our immunohistological analysis of wounded mouse
or human skin showed that Mfs and PMNs expressed L12-LO
or the human equivalent, h15-LO-1 (Funk et al., 2002), respec-
tively (Figure S2 and Table S1), demonstrating the existence of
L12-LO- or h15-LO-1-expressing Mfs and PMNs in wounds for
potential biosynthesis of 14S,22-diHDHA.
We sought to identify the specific P450 responsible for the
biosynthesis of 14,22-diHDHAs by incubating DHA or 14S/R-
HDHA with a human cytochrome P450 enzyme (h-P450) mixture
(BioCatalytics). The h-P450 mixture contained NADPH cofactor
and six h-P450s in fixed ratios (recombinant human CYP1A2,
2C8, 2C9, 2D6, 2E1, and 3A4). Targeted lipidomic analysis
with aR chiral LC-UV-MS/MS of the incubations showed that
these P450s did not generate 14,22-diHDHAs and nor did the
biosynthesis of the intermediate 22-HDHA, However, they con-
verted DHA to the intermediates 14S-HDHA and 14R-HDHA in329, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1321
Figure 4. Differential Activities of Human Monocytes, Neutrophils,
Lymphocytes, or Platelets or Macrophages of Diabetic db/db or
Nondiabetic db/+Mice in Producing 14S,22-diHDA, 14R,22-diHDHA,
and the Biosynthetic Intermediates or Markers 22-HDHA,
14S-HDHA, and 14R-HDHA
Human MCs (3 3 106), neutrophils (3 3 106), lymphocytes (3 3 106), or
platelets (3 3 108) or Mfs of db/db or db/+ mice were incubated in 3 mM DHA
and then stimulated as in Figure 1. The incubations were analyzed using aR
chiral LC-UV-MS. For Mfs of db/db or db/+ mice, the medium also contained
25 mM glucose. Results are mean ± SEM (n = 4). *p < 0.05, **p < 0.01 versus
neutrophils; #p < 0.05 versus db/+ Mfs.
See also Figures S2 and S3 and Table S1.
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1322 Chemistry & Biology 21, 1318–1329, October 23, 2014 ª2014 Ea racemic 1:1 ratio (Figure S1). Therefore, human CYP1A2, 2C8,
2C9, 2D6, 2E1, and 3A4 did not catalyze 22-hydroxylation/
u-oxidation of either DHA, 14S-HDHA, or 14R-HDHA but did
catalyze 14S-hydroxylation and 14R-hydroxylation of DHA,
which could contribute to the biosynthesis of 14,22-diHDHAs
from DHA. However, as we concluded above, the amount
of 14S-hydroxylation catalyzed by P450 is relatively minor
compared with the amount catalyzed by P12-LO in PLTs and
L12-LO or h15-LO-1 in leukocytes.
Different Activities of Monocytes, PMNs, Lymphocytes,
and Platelets of Humans as well as Macrophages of
Diabetic and Nondiabetic Mice in the Biosynthesis of
14S,22-DiHDA and 14R,22-DiHDHA
To compare the activities of human PLTs, PMNs, LYMs, and
MCs (Mf precursors) in the biosynthesis of 14S,22-diHDA and
14R,22-diHDHA from DHA, we quantified them and their biosyn-
thetic intermediates or markers 14S-HDHA, 14R-HDHA, and 22-
HDHA following incubation with DHA (wound level) (Figure 4).
MCs produced 8 times as much 14S,22-diHDHA and twice
as much 14R,22-diHDHA compared with PMNs, whereas
LYMs did not produce a detectable amount of 14,22-diHDHAs.
The blood of healthy humans contains 3 3 108 PLTs/ml and
6 3 106 leukocytes/ml (Handin et al., 2003). We found that
3 3 108 PLTs produced 65% as much 14S,22-diHDHA as
3 3 106 MCs but a similar amount of 14R,22-diHDHA. Biosyn-
thesis of the 14S-HDHA intermediate by PLTs and MCs was at
much higher levels than by PMNs or LYMs, which correlated
with the production of 14S,22-diHDHA by these populations.
Biosynthesis of 14R-HDHA (14R,22-diHDHA intermediate) by
PLTs and MCs exhibited a trend similar to that of 14S-HDHA
levels. Biosynthesis of 22-HDHA (an intermediate of both
14S,22-diHDHA and 14R,22-diHDHA) was highest in PMNs,
lower in PLTs, much lower in MCs, and undetectable in LYMs.
Levels of 14S,22-diHDHA produced by MCs, PMNs, or PLTs
were 17, 4, or 9 times higher than the respective levels
of 14R,22-diHDHA. Therefore, the rank order with respect to
biosynthesis of 14S,22-diHDHA and 14R,22-HDHA was MCs
(3 3 106 cells) R PLT (3 3 108 cells) > PMN (3 3 106 cells).
The data also suggest that LYMs do not produce these mole-
cules at a detectable level. Human plasma alone did not contain
or produce detectable 14S/R,22-diHDHA but can modestly
promote 14S/R,22-diHDHA production by blood cells, although
it did not change above the rank order (Figure S3).
Mfs differentiate from MCs and are able to convert DHA to
14,22-diHDHAs (Figure 3B). In an autocrine/paracrine manner,
Mfs produce lipid mediators and then use the lipid mediatorslsevier Ltd All rights reserved
Figure 5. Maresin-L, 14,22-diHDHA, Treatment Restored Diabetes-Impaired db/dbMacrophage Functions in PromotingWound Healing and
in Recruiting MSCs
Mfs were isolated from diabetic db/db or nondiabetic control db/+mice. Scratch wounds were generated in the monolayers of fibroblasts and epithelial cells in
dishes, which were then treated for 34 and 24 hr, respectively, with CM from db/db or db/+Mfs cultured without or with maresin-Ls (14,22-diHDHAs) (0, 10, or
50 nM). Wound healing was percent of cell densities recovered in the original wound zone relative to the control without CM. MSC transmigration was started by
addingmurineMSCs into the upper chambers of transwells and adding CMof db/db or db/+Mfs cultured without or with 14,22-diHDHAs (0, 10, or 50 nM) into the
lower chamber. The transmigration was expressed as percent of migrated MSCs relative to control without CM. Results are mean ± SEM (n = 4). *p < 0.01
compared with CM of db/dbMfs without maresin-L treatment. Quantitative results are shown on the left, and representative microphotographs are shown in the
center. The cell morphologies are shown on the right.
(A) Scratch wound healing of fibroblasts in CM of Mfs.
(B) Scratch wound healing of epithelial cells in CM of Mfs.
(C) Transmigration of MSCs toward CM of Mfs.
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(Serhan et al., 2009; Tian et al., 2011b). We predicted that
diabetes may affect Mf production of 14,22-diHDHAs because
diabetes impairs Mf functions. This prediction was tested by
comparative studies of Mfs of diabetic db/db mice and nondia-
betic control db/+ mice. We found that db/+ Mfs produced
more 14S,22-diHDHA from DHA than db/dbMfs (Figure 4), indi-
cating that there was a deficiency of 14,22-diHDHA generation
by diabetic Mfs. 25 mM glucose for 24 hr did not affect db/+
Mf production of 14,22-diHDHA compared with 5 mM glucose
(data not shown).
Bioactions of 14,22-diHDHAs on Diabetes Impaired
Reparative Functions of Macrophages
Because Mfs, MCs, PMNs, and PLTs produce 14,22-diHDHAs
and play crucial roles in healing (Figures 1, 3, and 4), because
diabetes impairs Mf 14,22-diHDHA-formation (Figure 4) andChemistry & Biology 21, 1318–1reparative functions, and because Mf-produced 14S,21R-
diHDHA restores the functions of diabetic Mfs (Tian et al.,
2011b), we were motivated to test our second hypothesis that
14,22-diHDHAs act as autocrine/paracrine factors capable of
restoring diabetes-impaired Mf functions. We assessed the ef-
fect of 14,22-diHDHAs on the reparative functions of Mfs from
diabetic db/db mice in wound healing of fibroblasts or epithelial
cells. Mfs from diabetic db/db mice were treated with 14,22-
diHDHAs (14S,22-diHDHA:14R,22-diHDHA, 10:1) at different
concentrations (24 hr, 37C). The medium from the Mf cultures
was used as Mf-conditioned medium (CM). 14,22-diHDHAs
were undetectable by aR chiral LC-MS/MS in the medium after
conditioning. Compared with the conditioned medium from
nondiabetic db/+ Mfs, the conditioned medium from diabetic
db/db Mfs was incapable of promoting the migration of
scratch-wounded fibroblasts (Figure 5A) or epithelial cells (Fig-
ure 5B). However, treatment of db/db Mfs with 14,22-diHDHAs,329, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1323
Figure 6. Maresin-L, 14,22-diHDHA, Treatment Increased db/db
Macrophage Expression of HGF but Decreased db/db Macrophage
Production of TNFa and TXB2 under Hypoxia and High-Glucose
Conditions Relevant to Diabetic Wounds
Macrophages (Mfs) isolated from diabetic db/db or nondiabetic control db/+
mice were cultured in medium containing 0, 10, or 50 nM maresin-Ls and
25 mM glucose under hypoxia (95% N2, 5%CO2, 24 h). For comparison, Mfs
isolated from nondiabetic db/+ mice were cultured in medium without
maresin-Ls and with normal glucose (5 mM) under hypoxia (95% N2, 5%CO2,
24 h). The Mf-conditioned media were analyzed for HGF, TNFa, and TXB2 by
ELISA. Results aremean ± SEM (n = 3). *p < 0.05, **p < 0.01 comparedwith CM
of db/db Mfs without maresin-L treatment; #p < 0.05 compared with CM of
db/+ Mfs without maresin-L treatment and with normal glucose.
(A) HGF.
(B) TNFa.
(C) TXB2.
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1324 Chemistry & Biology 21, 1318–1329, October 23, 2014 ª2014 Eeven at concentrations as low as 10 nM, restored the reparative
activity of db/db Mfs on promoting migration of scratch-
wounded fibroblasts or epithelial cells. Both 14,22-diHDHAs
and maresins are 14-hydroxy-carrying autocrine/paracrine do-
cosanoids of Mfs because they are produced by Mfs and regu-
late Mfs (Serhan et al., 2009). Maresins also potently enhance
Mf reparative functions. Therefore, 14,22-diHDHAs are denoted
‘‘maresin-like (maresin-L).’’
Wenext studied the effect ofmaresin-Ls ondb/dbMfmigration
of MSCs using a transmigration assay becauseMSCs can accel-
erate healing by producing paracrine factors and replenishing
cells lost in wounds (Phinney and Prockop, 2007). Conditioned
medium from nondiabetic db/+ Mfs stimulated transmigration
of MSCs from the upper chamber, whereas conditioned medium
from diabetic db/dbMfs did not. However, conditioned medium
from db/db Mfs treated with maresin-Ls, in a nanomolar range,
enabled db/db Mfs to produce conditioned medium that signifi-
cantly stimulated transmigration of MSCs from the upper cham-
ber (Figure 5C). Therefore, maresin-L treatment could rescue
diabetes-impaired functions of Mfs in recruiting MSCs.
ActivatedMfsproduceHGF (Yinet al., 2014),whichaccelerates
woundhealingandMSCmigration.Wepostulated that aplausible
mechanism by which maresin-Ls restored the reparative func-
tions of db/db Mfs might, in part, be augmenting prohealing
growth factor production. To test this, we used ELISA to
quantify HGF in conditioned medium from db/db and db/+ Mfs
and maresin-L-treated db/db Mfs. The results showed that HGF
secretionbydb/dbMfswassignificantly less thanbydb/+Mfsun-
der simulated selected diabetic wound conditions (hypoxia and
high glucose) (Figure 6A), consistent with the impaired functions
of db/db Mfs (Figure 5). The deficiency of db/db Mfs was cor-
rected by treatment with maresin-Ls, which promoted HGF pro-
duction in a dose-dependent manner (Figure 6A). This recovery
of HGF production may be involved in the rescue of db/db Mf
functions in wound healing and MSC transmigration (Figure 5).
Excessive chronic inflammation and sustained inflammatory
activation of Mfs are major causes of nonhealing of diabetic
wounds (Khanna et al., 2010; Tian et al., 2011b). Diabetic db/
dbMfs produced significantly more inflammatory tumor necrosis
factor a (TNFa) and thromboxane A2 (TXA2, detected as its stable
derivative, TXB2) compared with nondiabetic db/+ Mfs under
simulated selected diabetic wound conditions (Figures 6B and
6C), indicating excessive inflammatory activation of db/db Mfs.
At the nanomolar range, maresin-Ls considerably reduced the
levels of TNFa and TXA2 produced by db/db Mfs in a dose-
dependent manner (Figures 6B and 6C). These data indicate
that maresin-Ls reduced inflammatory activation of diabetic
Mfs by reducing their TNFa and TXA2 production, which could
be beneficial in the healing of diabetic wounds. Culture with
25 mM glucose for 24 hr increased db/+ Mf production of
TNFa and TXB2 but had no effect on HGF production.
DISCUSSION
The Maresin-like Docosanoids 14S,22-diHDHA and
14R,22-diHDHA Are Generated by Leukocytes
and Platelets
The cellular and molecular mechanisms for the crucial roles of
leukocytes and PLTs in injury repair are emerging and remainlsevier Ltd All rights reserved
Figure 7. Schematic Outlining the Tentative Biosynthetic Pathways and Bioactions of u-Hydroxy Maresin-like Docosahexaenoic Mediators
Generated by Leukocytes and Platelets
DHA is transformed by leukocytes and platelets via h15-LO-1 or L12-LO (12/15-LO) and P12-LO, respectively, to 14S-hydroperoxy-DHA (14S-HpDHA), which is
reduced to 14S-HDHA. These cells further convert 14S-HDHA to 14S,22-diHDHA (maresin-L1) through P450-catalyzed u(22)-oxidation. Alternatively, by P450
activities of the cells, DHA is first transformed to 14S-HDHA, 14R-HDHA, and 22-HDHA. Then 14R-HDHA is converted by P450 to 14R,22-diHDHA (maresin-L2).
The double bond geometries of 14S (or R)-HDHA are conserved after being converted to maresin-Ls based on our results and reported analogous data
for eicosanoids. This conservation also applies to the transformation of DHA to 22-HDHA. Maresin-Ls represent autocrine/paracrine factors that are produced
by monocytes, macrophages, neutrophils, and/or platelets. They act on macrophages in the promotion of wound healing and MSC transmigration. See also
Figure S4.
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terized two u-hydroxy docosahexaenoids, 14S,22-diHDHA
(maresin-L1) and 14R,22-diHDHA (maresin-L2), that are gener-
ated from DHA by leukocytes and/or PLTs. We performed struc-
tural elucidation by aR chiral LC-UV-MS/MS spectroscopy
and chromatography, including use of deuterium-labeled iso-
topomers (Wang et al., 2013). The chiralities of the two 14,22-
diHDHA stereoisomers were identified. The knowledge of
activities of PLTs and each type of leukocyte in 14,22-diHDHA
biosynthesis are the basis to harnessing these activities for
wound healing treatment.
Our data indicate different capabilities for biosynthesis of
14S,22-diHDHA and 14R,22-HDHA by different cell types. We
found that the rank of production was MCs R PLTs > PMNs.
LYMs did not produce these molecules at a detectable level.
These findings suggest differential contributions from different
blood cells for generation of 14,22-diHDHAs and differential
roles for 14,22-diHDHAs as autocrine or paracrine factors in
the functions of these cells in wound healing.
P450 and 12-LO Are Responsible for the Biosynthesis of
Maresin-L1 andMaresin-L2 by Leukocytes andPlatelets
Based on the results, we propose tentative biosynthetic path-
ways for 14,22-diHDAs (Figure 7; Figure S4). We found that inhi-
bition of P450 of leukocytes and PLTs and knockout of L12-LO
in murine Mfs suggest the following. (1) P450 is responsible for
22-hydroxylation/u-oxidation to produce 14,22-diHDHAs from
either DHA, 14S-HDHA, or 14R-HDHAaswell as for 14R-hydrox-
ylation to produce 14R,22-diHDHA from DHA or 22-HDHA. (2)
Auto-oxidation, cyclooxygenases, and 5-LO are negligible for
the biosynthesis of these compounds. P450 plays a minor role
in DHA 14S-hydroxylation for biosynthesis of 14S,22-diHDHA
and 14S-HDHA. This is consistent with a previous report
showing that cyclooxygenases did not produce 14-HDHA (Ser-
han et al., 2002). (3) P12-LO, L12-LO, and/or h15-LO-1 have a
dominant role, whereas P450 has a minor role in DHA 14S-
hydroxylation for the biosynthesis of 14S,22-diHDHA. These re-
sults are consistent with a report showing that LO inhibition byChemistry & Biology 21, 1318–1esculetin or L12-LO/ blocks formation of 14S-HDHA from
DHA in leukocyte-rich exudates from peritonitis (Serhan et al.,
2009).
Out data indicate that human CYP1A2, 2C8, 2C9, 2D6, 2E1,
and 3A4 do not catalyze 22-hydroxylation of DHA or 14R/
S-HDHA but catalyze DHA 14R/S-hydroxylation (Figure S1),
although the 14S-hydroxylation catalyzed by P450 is much
less than that catalyzed by P12-LO in PLTs and h15-LO-1 or
L12-LO in leukocytes. It is very likely that the 22-hydroxylation
of DHA or 14S/R-HDHA for 14,22-diHDHAbiosynthesis are cata-
lyzed by the P450 CYP4 family because these P450s are respon-
sible for u-hydroxylation of fatty acids and eicosanoids (Kikuta
et al., 2002). Moreover, CYP4F is expressed in human leuko-
cytes (Kikuta et al., 2004). Mouse CYP4F18 is an ortholog of hu-
man PMN CYP4F3A (Christmas et al., 2006). CYP1A1, 2U1, 2J2,
4A11, 4F2, and 5A1 are expressed as both proteins and mRNAs
in PLTs (Jarrar et al., 2013). Systematic studies are needed to
define the specific P450s responsible for 14,22-diHDHA forma-
tion in leukocytes and PLTs.
The major enzymes for the biosynthesis of DHA-derived medi-
ators in human MCs and PMNs are 5-LO, h15-LO-1, and P450,
whereas, in mouse Mfs, they are 5-LO, L12-LO, and P450. In
PLTs, they are P12-LO and P450 (Ikei et al., 2012; Serhan
et al., 2009). Our data suggest that the h15-LO-1 in human leu-
kocytes, L12-LO in mouse Mfs, and P12-LO in PLTs were
responsible for DHA 14S-hydroxylation for 14S,22-diHDHA
biosynthesis. The ratio of 14S-HDHA to 14S,22-diHDHA, as pro-
duced by PLTs, is 1017/1.5z670, whereas, for MCs or PMNs, it
is 40/2.3 z17 or 1.7/0.3 z6, respectively (Figure 4). Conse-
quently, the excess PLT-produced 14S-HDHA may be trans-
ferred to adjacent leukocytes and converted by leukocytes to
14S,22-HDHA, similar to the transcellular biosynthesis of lipox-
ins by PLTs and leukocytes (Serhan and Romano, 1995).
A number of Mfs and PMNs expressed L12-LO or h15-LO-1,
respectively, in wounded skin of mice or humans (Figures
S2A–S2D). We also found intermediates or pathway markers,
14R/S-HDHA and 22-HDHA, for the biosynthesis of 14,22-
diHDHAs in mouse wounded skin (Figures S2E and S2F).329, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1325
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14,22-diHDHAs might be produced by the Mfs and PMNs in
wounds via L12-LO or h15-LO-1. If so, then these molecules
might have acted on local cells and been degraded by the tissue
before our analysis.
In aggregate (Figure 7), our results indicate that the biosyn-
thesis of 14S,22-diHDHA by PLTs and leukocytes includes
14S-hydroxylation of DHA, which is determined by P12-LO
and L12-LO or h15-LO-1, respectively. The 14S-HDHA is then
hydroxylated at C22 by MCs, PLTs, and/or PMNs via P450 to
14S,22-diHDHA. Alternatively, by P450, DHA is first converted
to 14S-HDHA, 14R-HDHA, and 22-HDHA, and then, the last
two are further converted to 14R,22-diHDHA. 22-HDHA could
be converted to 14S,22-diHDHA via 14S-hydroxylation as
above. It could also be converted to 14R,22-diHDHA via 14R-
hydroxylation catalyzed by P450 (Figure S3). The double
bond geometries of DHA, 14R/S-HDHAs, and 22-HDHA are
conserved after conversion of the intermediates to 14,22-
diHDHAs, based on our results and according to reported anal-
ogous data for eicosanoids (Capdevila et al., 2005; Hong et al.,
2003). Therefore, 14,22-diHDHAs produced by leukocytes and/
or PLTs are 14S/R,22-dihydroxy docosa-4Z,7Z,10Z,12E,16Z,
19Z-hexaenoic acids.
Maresin-L1 and Maresin-L2 Act as Autocrine/Paracrine
Factors to Diminish Diabetic Impairment of Macrophage
Reparative Functions
We sought to identify natural lipid molecules produced by leuko-
cytes and PLTs that can diminish the diabetic impairment of Mf
reparative functions. Diabetic db/db Mfs were deficient in pro-
moting migration of epithelial cells and fibroblasts and in the
transmigration of MSCs compared with nondiabetic db/+ Mfs
(Figure 5), which was associated with the deficiency of 14,22-
diHDHA (maresin-L) production by db/dbMfs (Figure 4). Treating
db/dbMfs with maresin-Ls recovered the Mf reparative capabil-
ities. These results suggest that maresin-Ls, as autocrine/para-
crine factors produced by PLTs and leukocytes, including Mfs,
act on Mfs to diminish the diabetic impairment of Mf reparative
functions. Furthermore, the association of decreased formation
of maresin-Ls with impaired reparative functions of db/db Mfs
suggests that the impairment of Mf function in diabetes also in-
volves an impaired formation of these autocrine/paracrines.
14S/R,22-diHDHA is likely to mainly affect wound healing locally
after the blood cells enter the wounds because 14S/R,22-
diHDHA is likely to be produced by these cells, mostly in wounds
where there were more stimuli than in the circulation as injury
stimuli come from wounds. However, if the wounding is severe
enough to change the blood microenvironment, as severe burns
do, it may activate blood cells to produce sufficient amounts of
14S/R,22-diHDHA in the circulation, which may have systemic
effects on healing.
Maresin-L treatment ameliorates the diabetic impairment of
Mf production of HGF, a growth factor that regulate the cellular
processes responsible for wound repair, including stem cell
transmigration, re-epithelialization, angiogenesis, and collagen
deposition. The mechanism by which maresin-Ls restore Mf
reparative functions in diabetes may include the promotion of
Mf HGF expression. This implies that maresin-Ls restore dia-
betes-impaired paracrine functions in db/db Mfs.1326 Chemistry & Biology 21, 1318–1329, October 23, 2014 ª2014 EDiabetic wounds are characterized by chronic inflammation
and sustained inflammatory activation of Mfs (Brem and
Tomic-Canic, 2007), exemplified by increased production of in-
flammatory TNFa and TXA2 by db/db Mfs (Figures 6B and 6C).
Chronic inflammation in wounds retards the healing process
and damages tissue and is largely responsible for delayed
healing of diabetic wounds. Maresin-Ls reduced TNFa and
TXA2 generation by diabetic Mfs. Our results suggest that mare-
sin-Ls produced by leukocytes and PLTs are likely able to reduce
the excess inflammatory activation of diabetic Mfs, which is the
major driver of chronic inflammation in the middle and late heal-
ing phases in diabetic wounds (Khanna et al., 2010). Therefore,
maresin-Ls could also promote healing by reducing chronic
inflammation via an Mf-associated mechanism.
The ratio of M2 to M1-like Mfs is higher in db/+ wounds than
that in db/db wounds (Bannon et al., 2013), and M2 Mfs express
much more 12/15-LO than M1 Mfs (Biswas and Mantovani,
2012). Therefore, the diabetes-reduced population percentage
of M2-like or 12/15-LO-expressing Mfs may contribute to the
deficiency of 14,22-diHDHA production by db/dbMfs. However,
diabetes may also dysregulate the P450s for the biosynthesis
and metabolism of 14,22-diHDHA, similar to the dysregulation
of enzyme systems involved in the biosynthesis and metabolism
of eicosanoids (Ka¨mpfer et al., 2005; Kapoor et al., 2006). These
potential mechanisms need to be studied systematically studied
in the future.
In this report, we studied the actions of maresin-Ls in vitro. We
focused on the actions of factors secreted from Mfs after treat-
ment with maresin-Ls. However, the direct contact of Mfs with
other cells may have additional consequences and should be
studied systematically. Maresin-Ls may also be active on other
leukocytes, such as T cells, PMNs, master cells, dendritic cells,
and so forth, which also deserve to be investigated. The thiogly-
collate-elicited peritoneal Mfs used here exhibit some similarities
to skin wound Mfs on the studied aspects, including the dia-
betes-affected production of TNFa and IL10 as well as the pro-
motion of diabetic wound healing (Khanna et al., 2010; Koh
andDiPietro, 2011; Tian et al., 2011b). This is consistent with dia-
betes-impaired phagocytosis by zymosan-elicited Mfs of db/db
mice (Tang et al., 2013). However, rat wound Mfs can induce
apoptosis of PMNs. Rat Propionibacterium acnes-elicited peri-
toneal Mfs cannot induce PMN apoptosis (Meszaros et al.,
1999), indicating that there is a possible behavior difference be-
tween mouse wound macrophages and mouse thioglycollate-
elicited peritoneal Mfs in regard to PMN apoptosis. Therefore,
our results using thioglycollate-elicited peritoneal Mfs should
be confirmed further by in vivo experiments of skin wound heal-
ing in conjunction with using skin wound Mfs. Nonetheless, our
results are of translational significance because they appear to
provide a basis for further preclinical studies on the application
of maresin-Ls for restoration of diabetes-impaired Mf reparative
functions in diabetic wounds. The regulatory mechanisms gov-
erning the bioactions of each maresin-L on diabetic Mf functions
related to the impairment of injury repair need to be elucidated.
Our findings may provide mechanistic insights for reparative
functions of leukocytes and PLTs and provide molecular struc-
ture templates of maresin-Ls (14,22-diHDHAs) that may prove
valuable in the development of therapeutics for the treatment
of diabetic wounds (Brem and Tomic-Canic, 2007; Martin, 1997).lsevier Ltd All rights reserved
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Leukocytes and PLTs play crucial roles in wound healing by
mechanisms that need to be determined further. We identi-
fied two maresin-L docosahexaenoic mediators, 14S,22-
diHDHA (maresin-L1) and 14R,22-diHDHA (maresin-L2), and
demonstrated their potential to restore diabetes-impaired
Mf reparative functions. Maresin-Ls are biosynthesized by
MCs, Mfs, PLTs, and PMNs. We found that the biosynthetic
pathways for maresin-Ls require 12-LO-initiated 14S-
hydroxylation or cytochrome P450-catalyzed 14R-hydroxyl-
ation and P450-catalyzed u(22)-hydroxylation of DHA.
Maresin-L treatment restores reparative functions to dia-
betic Mfs, enabling their promotion of migration of fibro-
blasts and epithelial cells, the cellular processes known to
be critical to wound healing, and migration of mesenchymal
stemcells viamechanisms thatmay include enhancement of
Mf production of HGF.Maresin-L treatment also ameliorates
the inflammatory activation of diabetic Mfs. Therefore, mar-
esin-Ls have the potential to suppress the chronic inflamma-
tion in diabeticwounds caused by inflammatory activation of
Mfs. These data suggest that maresin-Ls act as autocrine/
paracrine factors responsible for, at least in part, the repara-
tive functions of leukocytes and PLTs in wounds. These
findings may provide mechanistic insights into the roles of
leukocytes and PLTs in wound healing and offer a therapeu-
tic option of usingmaresin-L-rescued diabeticMfs for better
treatment of diabetic wounds.
EXPERIMENTAL PROCEDURES
Materials
DHA, DHA-d5, 14R/S-HDHA, and 17-ODYA were from Cayman.
Animals
All procedures involving animals followed animal protocols approved by the
Institutional Animal Care and Use Committees of our institutes. Diabetic db/
db (BKS.Cg-m+/+leprdb) and nondiabetic db/+ mice (11 weeks old, female)
(Jackson Laboratory) were used when blood glucose was 25–35 mM for
db/db mice and 5–10 mM for db/+ mice. L12-LO/ and wild-type C57BL/
6J control mice were 11-week-old females (Jackson Laboratory).
Isolation of Human Platelets, PMNs, Monocytes, and Lymphocytes
Human samples were obtained following protocols approved by the Institu-
tional Review Boards of our institutes. Established procedures were followed
(Hong et al., 2003; Serhan and Romano, 1995). Human whole blood provided
by the Blood Center was from a healthy donor who was unknown to us and
who had not been on medication for >2 weeks prior to donation. The blood
in sodium citrate was centrifuged (180 3 g, 10 min, 23C). Then the superna-
tantswere centrifuged (11003 g, 15min, 23C). The top layer was plasma. Cell
pellets were washed with 7 mM EDTA, which yielded PLTs with a purity of 1
leukocyte/3 3 104 PLTs. PMNs and mononuclear cells were isolated from
blood by Ficoll-Hypague gradient. The mononuclear cells were plated onto
plastic dishes. The cells adhered to the dishes were MCs. and nonadhered
cells were LYMs. The PMNs, MCs, and LYMs prepared were of >96% purity.
The viability of cells was >95% according to trypan blue exclusion.
Isolation of Mouse Macrophages
Mouse Mfs were isolated and identified as reported previously (Tian et al.,
2011b).Mice (db/db, db/+, L12-LO/, or C57BL/6J) were treatedwith thiogly-
collate for 3 days. Cells were collected by peritoneal lavage and plated in RPMI
1640 medium onto plastic dishes (24 hr, 37C, 5% CO2). The adherent cells
were harvested, which yielded more than 95% F4/80+ Mfs (Tian et al., 2011b).Chemistry & Biology 21, 1318–1Biosynthesis of Docosanoids
14S-HDHA was generated from DHA by porcine L12-LO (Cayman) and iso-
lated by aR chiral LC-UV-MS/MS (Thermo Scientific) with an AD-RH or IA chiral
column (150 mm long3 2.1 mm inner diameter3 5 mm, Chiral Tech) (Lu et al.,
2010), or 14S-HDHA and 14R-HDHA were separated from racemic 14S/R-
HDHAs (Cayman) by aR chiral-LC-UV-MS/MS (Lu et al., 2010). In experiments
involving cellular production of docosanoids, human PMNs (33 106), MCs (33
106), LYMs (3 3 106), PLTs (3 3 108), leukocytes (3 3 106 PMNs + 3 3 106
MCs + 3 3 106 LYMs), leukocytes plus PLTs (3 3 106 PMNs + 3 3 106
MCs + 3 3 106 LYMs + 3 3 108 PLTs), or Mfs (3 3 106) of L12-LO/,
C57BL6, db/db, or db/+mice were incubated (20min, 37C) in PBS containing
3 mMDHA, DHA-d5, 14S-HDHA, or 14R-HDHA. The cells were then stimulated
(37C, 30 min) with 10 ng/ml TNFa, 10 ng/ml IL-1b, 100 ng/ml lipopolysaccha-
ride, and 1 U/ml thrombin (if PLTs were added). For Mfs of db/db or db/+mice,
the media contained 25 mM glucose to simulate diabetic hyperglycemia or
5 mM for normal glucose control. DHA has been reported to be 3 mmol/kg
in wounded skin of db/+ and db/db mice (Tian et al., 2011a). Therefore,
3 mMDHA is physiologically relevant to wound healing. To inhibit P450, human
leukocytes plus PLTs (33 106 PMNs + 33 106 MCs + 33 106 LYMs + 33 108
PLTs) were treated with a P450 inhibitor, 50 mM 17-ODYA, or vehicle control
(0.005% DMSO) (10 min, 37C) (Chiang et al., 1998; Muerhoff et al., 1989).
The incubation was continued for 20 min after adding DHA (3 mM), followed
by addition of the same amount of 17-ODYA. Then it was stimulated as above.
Analysis and Preparation of 14,22-diHDHAs Using aR Chiral LC-UV-
MS/MS
The final incubations were extracted and analyzed or fractionated for docosa-
noids using aR chiral LC-UV-MS/MS, as we published previously (Lu et al.,
2010; Tian et al., 2011a). For the AD-RH column, the mobile phase flowed at
0.15 ml/min. It eluted as D (acetonitrile:H2O:acetic acid = 45:55:0.01) from
0–45 min, ramped to acetonitrile from 45.1–60 min, and then flowed as aceto-
nitrile. For the IA column, the mobile phase flowed at 0.2 ml/min, eluted as B
(methanol:H2O:acetic acid = 27:73:0.01) from 0–1 min, ramped from B:meth-
anol 40:60 to B:methanol 20:80 by 50 min, ramped to methanol by 55 min, and
then flowed as methanol. The incubation of leukocytes plus PLTs with DHA
were fractionated using the same aR chiral LC-UV-MS/MS as for the prepara-
tion of 14,22-diHDHAs. The isolated 14S,22-diHDHA or 14R,22-diHDHA were
98% pure based on LC-UV-MS/MS analysis. 14S,22-diHDHA and 14R,22-
diHDHA purified from incubations of [leukocytes + PLTs + DHA] were of an
10:1 ratio (in nanomoles) and, therefore, combined in a 10:1 ratio for the
studies of their bioactions. Prostaglandin E2-d4 (5 ng) was added to each incu-
bation as an internal standard for quantification after the biosynthesis was
stopped by methanol.
Conditioned Medium of Macrophages Treated by Hypoxia and
14,22-diHDHAs and Analysis of HGF, TNFa, and TXB2
db/db and db/+Mfs (33 105) were incubated in a hypoxia chamber (95% N2,
5%CO2) in fresh RPMI 1640 with 25 or 5 mM glucose and 14,22-diHDHAs at 0,
10, or 50 nM (24 hr). The final medium after the removal of debris did not
contain detectable 14,22-diHDHAs and was used as the conditioned medium.
HGF, TNFa, and TXB2 in conditioned medium were analyzed by ELISA kits
(R&D Systems). The hypoxia simulated the low O2 levels found in wounded
tissue (Fife et al., 2009; Kang et al., 2013).
Scratch Wounding In Vitro
Established procedures were followed with minor adjustments (Kenchegowda
et al., 2011). Mouse fibroblasts (CF-1, ATCC) and human epithelial cells (HK2,
ATCC) were grown to confluence in Eagle’s minimal essential medium with
15% fetal bovine serum (FBS) and DMEM/Ham’s F12 with 10% FBS, respec-
tively. Then each cell line was starved to quiescence in 0.5%FBS (12 hr, 37C).
Quiescent cell monolayers were scratch-wounded using a sterile 200 ml
pipette tip to generate a cell-denuded wound zone, washed, and incubated
with medium containing 0.5% FBS and 20% conditioned medium of Mfs
treated without or with 14,22-diHDHAs (0, 10, or 50 nM). The wound was al-
lowed to heal for 34 hr (for fibroblasts) or 24 hr (for epithelial cells), a point at
which cells inside the wound zone for different conditions had reached 0%–
90% confluence. The wounded areas were photographed under a phase
contrast microscope at320 magnification. The wound healing was quantified329, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1327
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wound zone relative to a control without conditioned medium (Tomic-Canic
et al., 2007).
Isolation of MSCs from Mice and Transmigration of MSCs
MSCswere isolated as described in our prior publications, andmore than 95%
of isolated MSCs were positive for Sca-1 and CD29 based on flow cytometric
analysis (Izadpanah et al., 2006; Tian et al., 2011a, 2012). Previously published
procedures were followed, with minor modifications, for the assay of MSC
transmigration (Kim et al., 2010). Briefly, mouse MSCs (4 3 105) were added
into the upper chamber of 24-well transwell plates (8 mm). Murine mesen-
chymal medium (STEMCELL Technologies) (600 ml), and conditioned medium
(200 ml) from Mfs treated without or with 14,22-diHDHAs (0, 10, 50 nM) was
added into the lower chamber. Migration was carried out for 4 hr at 37C.
The cells underneath the membrane were stained with Giemsa and counted
asmigrated cells. Migration wasmeasured as cell number per fivemicroscope
fields. Results are expressed as percent migrated MSCs compared to control
without conditioned medium.
Statistics
Results are reported as mean ± SEM and were analyzed by ANOVA, followed
by Fisher’s least significant difference post hoc comparison. p < 0.05 was
considered significant.
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